CL2017001090A1 - Inmunoglobulinas hetero-diméricas de redireccionamiento de células t cd3/cd38 y sus métodos de producción - Google Patents
Inmunoglobulinas hetero-diméricas de redireccionamiento de células t cd3/cd38 y sus métodos de producciónInfo
- Publication number
- CL2017001090A1 CL2017001090A1 CL2017001090A CL2017001090A CL2017001090A1 CL 2017001090 A1 CL2017001090 A1 CL 2017001090A1 CL 2017001090 A CL2017001090 A CL 2017001090A CL 2017001090 A CL2017001090 A CL 2017001090A CL 2017001090 A1 CL2017001090 A1 CL 2017001090A1
- Authority
- CL
- Chile
- Prior art keywords
- redirection
- cells
- production methods
- heterodimeric immunoglobulins
- human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2014/073738 WO2015063339A1 (fr) | 2013-11-04 | 2014-11-04 | Production de cellules t reciblant des immunoglobulines héréro-dimériques |
| EP15167034 | 2015-05-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017001090A1 true CL2017001090A1 (es) | 2018-01-05 |
Family
ID=53059011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017001090A CL2017001090A1 (es) | 2014-11-04 | 2017-05-02 | Inmunoglobulinas hetero-diméricas de redireccionamiento de células t cd3/cd38 y sus métodos de producción |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP3215541A1 (fr) |
| JP (3) | JP2018501297A (fr) |
| KR (1) | KR102760422B1 (fr) |
| CN (1) | CN107207596A (fr) |
| AU (1) | AU2015341884B2 (fr) |
| BR (1) | BR112017009263A2 (fr) |
| CA (1) | CA2965745C (fr) |
| CL (1) | CL2017001090A1 (fr) |
| CO (1) | CO2017005240A2 (fr) |
| EA (1) | EA039658B1 (fr) |
| HK (1) | HK1244014A1 (fr) |
| IL (1) | IL251848A0 (fr) |
| MA (1) | MA40894A (fr) |
| MX (1) | MX2017005814A (fr) |
| MY (1) | MY186929A (fr) |
| NZ (1) | NZ732019A (fr) |
| PE (1) | PE20171041A1 (fr) |
| PH (1) | PH12017500819A1 (fr) |
| SG (1) | SG11201703313SA (fr) |
| WO (1) | WO2016071355A1 (fr) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11434302B2 (en) | 2016-02-03 | 2022-09-06 | Amgen Research (Munich) Gmbh | Bispecific T cell engaging antibody constructs |
| US11447567B2 (en) | 2015-07-31 | 2022-09-20 | Amgen Research (Munich) Gmbh | Antibody constructs for FLT3 and CD3 |
| US11884720B2 (en) | 2015-07-31 | 2024-01-30 | Amgen Research (Munich) Gmbh | Antibody constructs for MSLN and CD3 |
| US12428491B2 (en) | 2016-02-03 | 2025-09-30 | Amgen Research (Munich) Gmbh | PSMA and CD3 bispecific T cell engaging antibody constructs |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12466897B2 (en) | 2011-10-10 | 2025-11-11 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
| CN105051069B (zh) | 2013-01-14 | 2019-12-10 | Xencor股份有限公司 | 新型异二聚体蛋白 |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| DK3406633T3 (da) | 2013-07-25 | 2022-03-28 | Cytomx Therapeutics Inc | Multispecifikke antistoffer, multispecifikke aktiverbare antistoffer og fremgangsmåder til anvendelse heraf |
| EP3066133A1 (fr) | 2013-11-04 | 2016-09-14 | Glenmark Pharmaceuticals S.A. | Production de cellules t reciblant des immunoglobulines héréro-dimériques |
| KR102497443B1 (ko) | 2014-03-28 | 2023-02-08 | 젠코어 인코포레이티드 | Cd38 및 cd3에 결합하는 이중특이적 항체 |
| AU2015292406B2 (en) * | 2014-07-25 | 2021-03-11 | Cytomx Therapeutics, Inc | Anti-CD3 antibodies, activatable anti-CD3 antibodies, multispecific anti-CD3 antibodies, multispecific activatable anti-CD3 antibodies, and methods of using the same |
| US11773166B2 (en) | 2014-11-04 | 2023-10-03 | Ichnos Sciences SA | CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| BR112017011166A2 (pt) | 2014-11-26 | 2018-02-27 | Xencor, Inc. | anticorpos heterodiméricos que se ligam a cd3 e cd38 |
| CA2967426A1 (fr) | 2014-11-26 | 2016-06-02 | Xencor, Inc. | Anticorps heterodimeriques se liant a l'antigene cd3 et a un antigene tumoral |
| TWI744242B (zh) | 2015-07-31 | 2021-11-01 | 德商安美基研究（慕尼黑）公司 | Egfrviii及cd3抗體構築體 |
| CN108699136B (zh) | 2015-12-07 | 2022-03-18 | Xencor股份有限公司 | 结合cd3和psma的异二聚抗体 |
| CA3026151A1 (fr) | 2016-06-14 | 2017-12-21 | Xencor, Inc. | Anticorps inhibiteurs de points de controle bispecifiques |
| MX2018016265A (es) | 2016-06-28 | 2019-07-04 | Xencor Inc | Anticuerpos heterodimericos que se unen al receptor 2 de somatostatina. |
| WO2018197502A1 (fr) * | 2017-04-24 | 2018-11-01 | Glenmark Pharmaceuticals S.A. | Anticorps bispécifiques de redirection de lymphocytes t pour le traitement de cancers positifs de l'egfr |
| WO2018224441A1 (fr) * | 2017-06-05 | 2018-12-13 | Numab Innovation Ag | Nouveaux anticorps anti-cd3 |
| EP3634998B8 (fr) * | 2017-06-05 | 2025-04-09 | Numab Therapeutics AG | Anticorps anti cd3 epsilon |
| EP3635002A1 (fr) * | 2017-06-08 | 2020-04-15 | Black Belt Therapeutics Limited | Anticorps permettant de moduler cd38 |
| EP3635001A1 (fr) | 2017-06-08 | 2020-04-15 | Black Belt Therapeutics Limited | Anticorps permettant de moduler cd38 |
| ES2911243T3 (es) * | 2017-08-10 | 2022-05-18 | Grifols Diagnostic Solutions Inc | Composiciones, procedimientos y/o kits que comprenden un dominio extracelular recombinante de cd38 humano |
| US11542338B2 (en) | 2017-08-16 | 2023-01-03 | Black Belt Therapeutics Limited | CD38 modulating antibody |
| KR102770107B1 (ko) | 2017-08-16 | 2025-02-20 | 블랙 벨트 테라퓨틱스 리미티드 | Cd38 조정 항체 |
| KR102770110B1 (ko) | 2017-08-16 | 2025-02-20 | 블랙 벨트 테라퓨틱스 리미티드 | Cd38 항체 |
| WO2019035938A1 (fr) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | Molécules multispécifiques se liant à bcma et leurs utilisations |
| AU2018347607B2 (en) | 2017-10-14 | 2025-08-21 | Cytomx Therapeutics, Inc. | Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof |
| KR20200085828A (ko) | 2017-11-08 | 2020-07-15 | 젠코어 인코포레이티드 | 신규의 항-pd-1 서열을 사용한 이중특이적 및 단일특이적 항체 |
| EP3773911A2 (fr) | 2018-04-04 | 2021-02-17 | Xencor, Inc. | Anticorps hétérodimères qui se lient à la protéine d'activation des fibroblastes |
| AU2019348606A1 (en) * | 2018-09-25 | 2021-04-15 | Ichnos Sciences S.A. | Antibody quantification in biological samples |
| KR102353568B1 (ko) * | 2018-11-14 | 2022-01-20 | 주식회사 헬릭스미스 | 안정성이 향상된 항 c-Met 항체 또는 그의 항원 결합 단편 |
| SG11202107941TA (en) * | 2019-01-23 | 2021-08-30 | Encefa | Cd31 competitors and uses thereof |
| WO2020182984A2 (fr) * | 2019-03-13 | 2020-09-17 | Ichnos Sciences SA | Glycosylation sans consensus d'anticorps bispécifiques |
| CA3139111A1 (fr) * | 2019-05-23 | 2020-11-26 | VelosBio Inc. | Molecules de liaison bispecifiques anti-ror1/anti-cd3 |
| WO2020250940A1 (fr) * | 2019-06-11 | 2020-12-17 | 小野薬品工業株式会社 | Agent d'immunosuppression |
| CN110551222B (zh) * | 2019-08-27 | 2023-06-06 | 重庆市畜牧科学院 | 一种新型双功能抗体及其用途 |
| CN112538114B (zh) * | 2019-09-20 | 2025-05-02 | 上海普铭生物科技有限公司 | 抗人cd38抗体及其应用 |
| TWI841790B (zh) * | 2019-09-30 | 2024-05-11 | 大陸商和鉑醫藥（上海）有限責任公司 | 靶向cd3的抗體、雙特異性抗體及其用途 |
| CN115362346A (zh) | 2020-03-19 | 2022-11-18 | 深圳纽迪瑞科技开发有限公司 | 一种应变感测膜、压力传感器、混合应变感测系统 |
| CN113493519B (zh) * | 2020-03-19 | 2022-12-27 | 浙江道尔生物科技有限公司 | 一种半衰期显著延长的治疗眼部血管新生疾病的融合蛋白 |
| WO2021216972A1 (fr) * | 2020-04-24 | 2021-10-28 | Memorial Sloan Kettering Cancer Center | Anticorps anti-cd3 et utilisations associées |
| US11919956B2 (en) | 2020-05-14 | 2024-03-05 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3 |
| EP4168450A2 (fr) * | 2020-06-17 | 2023-04-26 | Y-Mabs Therapeutics, Inc. | Anticorps anti-cd38 pour le traitement de maladies humaines |
| JP7773528B2 (ja) | 2020-08-19 | 2025-11-19 | ゼンコア インコーポレイテッド | 抗ｃｄ２８組成物 |
| CA3212665A1 (fr) | 2021-03-09 | 2022-09-15 | Xencor, Inc. | Anticorps heterodimeriques se liant a cd3 et a cldn6 |
| KR20230154311A (ko) | 2021-03-10 | 2023-11-07 | 젠코어 인코포레이티드 | Cd3 및 gpc3에 결합하는 이종이량체 항체 |
| US20250340637A1 (en) * | 2021-08-04 | 2025-11-06 | Abpro Corporation | Cd3 targeting antibodies and uses thereof |
| CN118108852B (zh) * | 2023-11-23 | 2025-11-18 | 浙江大学 | 一种抗啶虫脒单克隆抗体及其重组全长IgG表达质粒 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ548990A (en) * | 2004-02-06 | 2009-06-26 | Morphosys Ag | Anti-CD38 human antibodies and uses therefor |
| EP3312196B1 (fr) * | 2005-03-23 | 2019-07-17 | Genmab A/S | Anticorps dirigés contre cd38 pour le traitement du myélome multiple |
| KR20150139636A (ko) * | 2005-10-12 | 2015-12-11 | 모르포시스 아게 | 인간 ｃｄ38에 특이적인 완전 인간 ｈｕｃａｌ ｇｏｌｄ-유도 치료 항체들의 생성 및 프로파일링 |
| EP1914242A1 (fr) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Nouveau anticorps Anti-CD38 pour le traitement du cancer |
| KR101747103B1 (ko) * | 2009-06-26 | 2017-06-14 | 리제너론 파마슈티칼스 인코포레이티드 | 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체 |
| RU2606264C2 (ru) * | 2009-12-25 | 2017-01-10 | Чугаи Сеияку Кабушики Каиша | Способ полипептидной модификации для очистки полипептидных мультимеров |
| EP3613774A1 (fr) * | 2010-06-09 | 2020-02-26 | Genmab A/S | Anticorps diriges contre le cd38 humain |
| JOP20210044A1 (ar) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| US9683052B2 (en) * | 2011-03-25 | 2017-06-20 | Glenmark Pharmaceuticals S.A. | Hetero-dimeric immunoglobulins |
| EP2900696A1 (fr) * | 2012-09-25 | 2015-08-05 | Glenmark Pharmaceuticals S.A. | Purification d'immunoglobulines hétérodimères |
| EP2914302B1 (fr) * | 2012-11-05 | 2017-01-04 | MorphoSys AG | Anticorps radiomarqué et ses utilisations |
| EP3066133A1 (fr) * | 2013-11-04 | 2016-09-14 | Glenmark Pharmaceuticals S.A. | Production de cellules t reciblant des immunoglobulines héréro-dimériques |
-
2015
- 2015-11-02 MA MA040894A patent/MA40894A/fr unknown
- 2015-11-03 EA EA201790961A patent/EA039658B1/ru unknown
- 2015-11-03 KR KR1020177015252A patent/KR102760422B1/ko active Active
- 2015-11-03 HK HK18103440.0A patent/HK1244014A1/zh unknown
- 2015-11-03 CN CN201580072196.8A patent/CN107207596A/zh active Pending
- 2015-11-03 EP EP15790129.9A patent/EP3215541A1/fr not_active Withdrawn
- 2015-11-03 SG SG11201703313SA patent/SG11201703313SA/en unknown
- 2015-11-03 CA CA2965745A patent/CA2965745C/fr active Active
- 2015-11-03 NZ NZ732019A patent/NZ732019A/en unknown
- 2015-11-03 MX MX2017005814A patent/MX2017005814A/es unknown
- 2015-11-03 BR BR112017009263-8A patent/BR112017009263A2/pt not_active Application Discontinuation
- 2015-11-03 AU AU2015341884A patent/AU2015341884B2/en active Active
- 2015-11-03 MY MYPI2017701499A patent/MY186929A/en unknown
- 2015-11-03 WO PCT/EP2015/075628 patent/WO2016071355A1/fr not_active Ceased
- 2015-11-03 PE PE2017000802A patent/PE20171041A1/es unknown
- 2015-11-03 JP JP2017542319A patent/JP2018501297A/ja active Pending
-
2017
- 2017-04-23 IL IL251848A patent/IL251848A0/en unknown
- 2017-05-02 CL CL2017001090A patent/CL2017001090A1/es unknown
- 2017-05-03 PH PH12017500819A patent/PH12017500819A1/en unknown
- 2017-05-26 CO CONC2017/0005240A patent/CO2017005240A2/es unknown
-
2019
- 2019-07-23 JP JP2019135318A patent/JP2019214582A/ja active Pending
-
2021
- 2021-08-02 JP JP2021126392A patent/JP7403505B2/ja active Active
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11447567B2 (en) | 2015-07-31 | 2022-09-20 | Amgen Research (Munich) Gmbh | Antibody constructs for FLT3 and CD3 |
| US11884720B2 (en) | 2015-07-31 | 2024-01-30 | Amgen Research (Munich) Gmbh | Antibody constructs for MSLN and CD3 |
| US11434302B2 (en) | 2016-02-03 | 2022-09-06 | Amgen Research (Munich) Gmbh | Bispecific T cell engaging antibody constructs |
| US12428491B2 (en) | 2016-02-03 | 2025-09-30 | Amgen Research (Munich) Gmbh | PSMA and CD3 bispecific T cell engaging antibody constructs |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2965745C (fr) | 2023-12-05 |
| EP3215541A1 (fr) | 2017-09-13 |
| AU2015341884A1 (en) | 2017-06-08 |
| NZ732019A (en) | 2022-07-29 |
| KR102760422B1 (ko) | 2025-02-03 |
| WO2016071355A1 (fr) | 2016-05-12 |
| BR112017009263A2 (pt) | 2018-01-30 |
| JP2019214582A (ja) | 2019-12-19 |
| IL251848A0 (en) | 2017-06-29 |
| CA2965745A1 (fr) | 2016-05-12 |
| JP2021184722A (ja) | 2021-12-09 |
| AU2015341884B2 (en) | 2020-09-17 |
| HK1244014A1 (zh) | 2018-07-27 |
| PH12017500819A1 (en) | 2017-10-02 |
| JP2018501297A (ja) | 2018-01-18 |
| CN107207596A (zh) | 2017-09-26 |
| EA039658B1 (ru) | 2022-02-22 |
| PE20171041A1 (es) | 2017-07-19 |
| SG11201703313SA (en) | 2017-05-30 |
| MX2017005814A (es) | 2017-08-02 |
| JP7403505B2 (ja) | 2023-12-22 |
| KR20170078831A (ko) | 2017-07-07 |
| MY186929A (en) | 2021-08-26 |
| CO2017005240A2 (es) | 2017-10-31 |
| MA40894A (fr) | 2017-09-12 |
| EA201790961A1 (ru) | 2017-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017001090A1 (es) | Inmunoglobulinas hetero-diméricas de redireccionamiento de células t cd3/cd38 y sus métodos de producción | |
| CY1124993T1 (el) | Ετεροδιμερικα αντισωματα που δεσμευουν cd3 και cd20 | |
| CY1123236T1 (el) | Αντισωματα διπλης εξειδικευσης που δεσμευονται με cd38 και cd3 | |
| MX2021014956A (es) | Formulaciones subcutaneas de anticuerpos anti-cd38 y sus usos. | |
| CL2017001361A1 (es) | Anticuerpos heterodiméricos que se unen a cd3 y cd38 | |
| ECSP17011657A (es) | Conjugados de fármacos con anticuerpos anti-cdh6 | |
| MX2016009555A (es) | Proteinas de union y metodos para utilizarlas. | |
| CR20170511A (es) | Anticuerpos heterodiméricos que se unen a cd3 y a antígenos tumorales. | |
| CO2017006740A2 (es) | Anticuerpos anti–cd79b | |
| UY35399A (es) | Conjugados de fármacos con anticuerpos | |
| EP3186279C0 (fr) | Constructions d'anticorps pour cdh19 et cd3 | |
| MX384364B (es) | Anticuerpos anti-pd-l1 y sus usos de diagnóstico. | |
| UY36905A (es) | Anticuerpos neutralizantes de poliomavirus | |
| JO3791B1 (ar) | تركيبات و طرق الأجسام المضادة المستهدفة لـ bmp6 | |
| CO2018013298A2 (es) | Anticuerpos anti-gitr y sus usos. | |
| EA201691610A1 (ru) | Анти-jagged1 антитела и способы применения | |
| CY1125400T1 (el) | Νεα αντι-ανθρωπινα αντισωματα gpvi και χρησεις αυτων | |
| CL2016001753A1 (es) | Anticuerpo monoclonal humanizado que se une específicamente a netrina-1, composiciones farmacéuticas y usos del anticuerpo para el tratamiento del cáncer | |
| CL2017000212A1 (es) | Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso | |
| AR101671A1 (es) | Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso | |
| CL2020000920A1 (es) | Anticuerpo monoclonal anti-il-5ra. | |
| BR112018004733A2 (pt) | anticorpos do receptor de transferrina humana/ a-beta anti-humana biespecíficos e métodos de uso | |
| CR20170222A (es) | Anticuerpos heterodiméricos que se unen a cd3 y antígenos tumorales | |
| EA201892257A1 (ru) | Анти-cd3 антитела и способы применения |